Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: A prospective randomized active-controlled trial

Journal of Gastroenterology

Volumn 47, Issue 11, 2012, Pages 1186-1197

  Sanuki, Tsuyoshi ^a   Fujita, Tsuyoshi ^a   Kutsumi, Hiromu ^a   Hayakumo, Takanobu ^a   Yoshida, Shun ichi ^b   Inokuchi, Hideto ^c   Murakami, Manabu ^a   Matsubara, Yoshihiro ^d   Kuwayama, Hajime ^e,f   Kawai, Takashi ^g   Miyaji, Hideki ^h   Fujisawa, Takashi ⁱ   Terao, Shuichi ^j   Yamazaki, Yukinao ^k   Azuma, Takeshi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Tabata Gastrointestinal Hospital   (Japan)

^c HYOGO CANCER CENTER   (Japan)

^d Translational Research Informatics Center   (Japan)

^e State University of New York Upstate Medical University: College of Medicine   (United States)

^f DOKKYO MEDICAL UNIVERSITY   (Japan)

^g TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^h Miyaji Medical Clinic   (Japan)

ⁱ Kakogawa West City Hospital   (Japan)

^j Kakogawa East City Hospital   (Japan)

^k UNIVERSITY OF FUKUI HOSPITAL   (Japan)

more..

Author keywords

Low dose aspirin; Peptic ulcer; Rabeprazole; Randomized clinical trial

Indexed keywords

ACETYLSALICYLIC ACID; GEFARNATE; RABEPRAZOLE;

ADULT; AGED; ANEMIA; ARTICLE; BRAIN HEMORRHAGE; BRAIN INFARCTION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; COLON DIVERTICULOSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DUODENAL ULCER BLEEDING; DUODENUM ULCER; ESOPHAGITIS; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HAZARD RATIO; HUMAN; ILEUS; INCIDENCE; KIDNEY FAILURE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MODIFIED LANZA SCORE; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OPEN STUDY; PARALLEL DESIGN; PEPTIC ULCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RISK REDUCTION; STOMACH ULCER; SUBDURAL HEMATOMA; SUICIDE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AGED; ANTI-ULCER AGENTS; ASPIRIN; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGITIS; FEMALE; GEFARNATE; HUMANS; MALE; MIDDLE AGED; PEPTIC ULCER; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RECURRENCE;

EID: 84872273561     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-012-0588-x     Document Type: Article

References (23)

1. Tamura I, Fujita T, Tsumura H, Morita Y, Toyonaga T, Hirano S, et al. Low-dose aspirin-induced gastroduodenal mucosal injury in Japanese patients with arteriosclerotic disease. Intern Med. 2010;49:2537-45.
2. Nakayama M, Iwakiri R, Hara M, Ootani H, Shimoda R, Tsunada S, et al. Low-dose aspirin is a prominent cause of bleeding ulcers in patients who underwent emergency endoscopy. J Gastroenterol. 2009;44:912-8.
3. Sung JJ, Lau JY, Ching JY, Wu JC, Lee YT, Chiu PW, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med. 2010;152:1-9.
4. Garcia Rodriguez LA, Cea-Soriano L, Martin-Merino E, Johansson S. Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care. BMJ. 2011;343:d4094.
5. Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin. 2007;23:163-73.
6. Lai KC, Lam SK, Chu KM, Wong BC, Hui WM, Hu WH, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002;346:2033-8.
7. Yeomans N, Lanas A, Labenz J, Van Zanten SV, Van Rensburg C, Rácz I, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol. 2008; 103:2465-73.
8. Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, doubleblind, placebo-controlled trial. Lancet. 2009;374:119-25.
9. Ng FH, Wong SY, Lam KF, Chu WH, Chan P, Ling YH, et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology. 2010;138:82-8.
10. Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008;64: 935-51.
11. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet. 2005;20:153-67.
12. Kusano M, Shimoyama Y, Sugimoto S, Kawamura O, Maeda M, Minashi K, et al. Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol. 2004; 39:888-91.
13. Sugano K, Matsumoto Y, Itabashi T, Abe S, Sasaki N, Ashida K, et al. Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol. 2011; 46:724-35.
14. Laine L, Maller ES, Yu C, Quan H, Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology. 2004; 127:395-402.
15. Pilott A, Franceschi M, Longo MG, Scarcelli C, Orsitto G, Perri F, et al. Helicobacter pylori infection and the prevention of peptic ulcer with proton pump inhibitors in elderly subjects taking lowdose aspirin. Dig Liver Dis. 2004;36:666-70.
16. Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Sainz R. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther. 2002;16:779-86.
17. Hart J, Hawkey CJ, Lanas A, Naesdals J, Talley NJ, Thomson AB, et al. Predictors of gastroduodenal erosions in patients taking low-dose aspirin. Aliment Pharmacol Ther. 2010;31:143-9.
18. Davenport HW. Salicylate damage to the gastric mucosal barrier. N Engl J Med. 1967;276:1307-12.
19. Nishino M, Sugimoto M, Kodaira C, Yamade M, Shirai N, Ikuma M, et al. Relationship between low-dose aspirin-induced gastric mucosal injury and intragastric pH in healthy volunteers. Dig Dis Sci. 2010;55:1627-36.
20. Iijima K, Ara N, Abe Y, Koike T, Iwai W, Uno K, et al. Gastric acid secretion level modulates the association between Helicobacter pylori infection and low-dose aspirin-induced gastropathy. J Gastroenterol. 2011;46:612-9.
21. Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal, a special risk for late stent thrombosis. J Am Coll Cardiol. 2005;45:456-9.
22. Van Rossum LG, Laheij RJF, Vlemmix F, Jansen JBMJ, Verheugt FWA. Health-related quality of life in patients with cardiovascular disease-the effect of upper gastrointestinal symptom treatment. Aliment Pharmacol Ther. 2004;19:1099-104.
23. Nema H, Kato M. Comparative study of therapeutic effects of PPI and H2RA on ulcers during continuous aspirin therapy. World J Gastroenterol. 2010;16:5342-6.